Phase I Multiple System Atrophy contract award worth >$500k

IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new biopharmaceutical client to support its Phase I multiple system atrophy clinical trial. Multiple system atrophy (MSA) is a rare condition of the nervous system that causes gradual damage to nerve cells in the brain.

Conducted across investigator sites within the Unites States, the clinical trial will enrol patients with the parkinsonian subtype of MSA (MSA-P) to assess the safety, tolerability, and preliminary efficacy of GDNF gene therapy for this rapidly progressing condition.  For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), FDG-PET and DaT scans.

The study is worth more than >$500k over 4 years.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "IXICO is delighted to be awarded the contract for this MSA clinical trial reflecting IXICO's expertise in rare neurological indications. MSA is a rare neurodegenerative disorder afflicting up to 17,000 individuals in the U.S. and an estimated 23,000 in the EU. New cases of MSA in the U.S. are estimated at 1,900 per year, and the disorder affects men and women equally."

 

For further information please contact:

Walbrook PR Ltd

 +44 (0)20 7933 8780

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings

 

Date: 08/09/2021